Jupiter Endovascular Closes Financing Round for Vertex Clinical Program

October 7, 2025—Jupiter Endovascular, Inc. announced it has closed a Series B financing round that surpassed its $40 million target.

According to the company, the funds will be used to complete Jupiter’s ongoing SPIRARE II pivotal clinical trial, prepare for commercialization, and develop new clinical applications for its transforming fixation (TFX) platform technology.

The financing round was led by Sonder Capital, with participation from Senvest Management, LB Investment, and a new strategic corporate investor, stated Jupiter Endovascular.

The company advised the financing comes amid several milestones for its technology. First, it continues to enroll patients in the prospective, single-arm, multicenter SPIRARE II pivotal trial. The trial will enroll up to 145 patients with acute, intermediate-risk PE treated with the Vertex pulmonary embolectomy system at up to 25 sites in the United States and Europe.

Additionally, the first-in-human results from the SPIRARE I trial of the Vertex pulmonary embolectomy system with TFX will be presented Principal Investigator Professor Irene Lang, MD, on October 26 at TCT 2025 in San Francisco, California. SPIRARE I is a prospective, single-arm, multicenter study that enrolled 10 patients with acute, intermediate-risk PE treated with the Vertex pulmonary embolectomy system at two sites in Europe, noted Jupiter Endovascular.

In September 2025, the company announced FDA 510(k) clearance of the Vertex catheter incorporating TFX for the insertion of endovascular devices.